Valuation: Gyre Therapeutics, Inc.

Market Cap 472M 427M 395M 357M 672M 44.48B 696M 4.75B 1.88B 23.76B 1.77B 1.73B 75.42B P/E 2026 *
-15.7x
P/E 2027 * -21.5x
Enterprise Value 472M 427M 395M 357M 672M 44.48B 696M 4.75B 1.88B 23.76B 1.77B 1.73B 75.42B EV / Sales 2026 *
4.19x
EV / Sales 2027 * 3.2x
Free-Float
27.93%
Yield 2026 *
-
Yield 2027 * -
1 day+0.23%
1 week-9.45%
Current month-5.38%
1 month-35.77%
3 months-34.10%
6 months-40.80%
Current year-38.95%
1 week 4.09
Extreme 4.09
4.8
1 month 3.97
Extreme 3.97
7.1
Current year 3.97
Extreme 3.97
9.14
1 year 3.97
Extreme 3.97
9.14
3 years 3.97
Extreme 3.97
30.4
5 years 3.97
Extreme 3.97
30.4
10 years 3.97
Extreme 3.97
30.4
Date Insider Type Main position Quantity % Market Cap. Importance
03/08/26 Free

Director

40,000 0.0359%
03/08/26 Free

Director

40,000 0.0359%
10/06/26 Free

Director

40,000 0.0412%
Change 5-day change 1-year change 3-year change Capi.($)
+0.23%-9.45%-46.66%-52.11% 472M
-2.69%-0.48%+51.67%+69.09% 66.33B
-0.92%+7.67%+14.26%+90.92% 60.62B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.08%+109.47% 47.58B
-2.21%-2.47%+18.60%+36.89% 43.69B
-2.30%-10.40%+167.61%+776.79% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-36.55%+406.95% 26.58B
Average -0.53%-0.90%+29.32%+164.56% 41B
Weighted average by Cap. -0.83%+0.19%+37.13%+161.94%

Financials

2026 *2027 *
Net sales 113M 102M 94.41M 85.18M 161M 10.62B 166M 1.13B 450M 5.67B 423M 414M 18.01B 147M 133M 123M 111M 210M 13.88B 217M 1.48B 588M 7.41B 552M 541M 23.53B
Net income -28.85M -26.14M -24.18M -21.82M -41.12M -2.72B -42.57M -290M -115M -1.45B -108M -106M -4.61B -27.15M -24.6M -22.76M -20.53M -38.69M -2.56B -40.06M -273M -108M -1.37B -102M -99.72M -4.34B
Net Debt - -
Projected Income Statement - Annual - Gyre Therapeutics, Inc.
Logo Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.
Employees
625
Date Price Change Volume
13/11/26 $4.310 +0.23% 281,343
12/11/26 $4.300 +0.94% 173,995
11/11/26 $4.260 +0.71% 130,505
10/11/26 $4.230 -9.03% 141,063
09/11/26 $4.650 -2.31% 224,595
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Gyre Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.310USD
Average target price
18.67USD
Spread / Average Target
+333.10%
  1. Stock Market
  2. Stocks
  3. GYRE Stock